CL2008003787A1 - Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. - Google Patents

Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.

Info

Publication number
CL2008003787A1
CL2008003787A1 CL2008003787A CL2008003787A CL2008003787A1 CL 2008003787 A1 CL2008003787 A1 CL 2008003787A1 CL 2008003787 A CL2008003787 A CL 2008003787A CL 2008003787 A CL2008003787 A CL 2008003787A CL 2008003787 A1 CL2008003787 A1 CL 2008003787A1
Authority
CL
Chile
Prior art keywords
compound
psychiatric
schizophrenia
anxiety
parkinson
Prior art date
Application number
CL2008003787A
Other languages
English (en)
Inventor
Pinard Emmanuel
Knust Henner
Roche Olivier
Nettekoven Matthias
Rogers Evans Mark
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008003787A1 publication Critical patent/CL2008003787A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiátricos, neurológicos, ansiedad, depresión, esquizofrenia, Alzheimer, Parkinson, entre otras.
CL2008003787A 2007-12-21 2008-12-18 Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. CL2008003787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150294 2007-12-21

Publications (1)

Publication Number Publication Date
CL2008003787A1 true CL2008003787A1 (es) 2010-02-19

Family

ID=40568638

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003787A CL2008003787A1 (es) 2007-12-21 2008-12-18 Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.

Country Status (14)

Country Link
US (1) US7897627B2 (es)
EP (1) EP2234999A1 (es)
JP (1) JP5395808B2 (es)
KR (1) KR101204213B1 (es)
CN (1) CN101903372B (es)
AR (1) AR069849A1 (es)
AU (1) AU2008340421B2 (es)
BR (1) BRPI0821141A2 (es)
CA (1) CA2705411A1 (es)
CL (1) CL2008003787A1 (es)
IL (1) IL205665A (es)
PE (1) PE20091173A1 (es)
TW (1) TW200930362A (es)
WO (1) WO2009080533A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
NZ583487A (en) * 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101910142B (zh) * 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂
BRPI0908096A2 (pt) * 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
CA2722347A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CN102083820B (zh) * 2008-07-29 2013-07-17 弗·哈夫曼-拉罗切有限公司 作为食欲肽拮抗剂的吡咯烷-3-基甲基-胺
CA2736924C (en) * 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN102209537A (zh) * 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
ES2434247T3 (es) 2008-12-22 2013-12-16 Merck Patent Gmbh Formas polimórficas novedosas de dihidrogenofosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona y procesos de fabricación de las mismas
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
PL2491038T3 (pl) 2009-10-23 2016-10-31 Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny
JP5847087B2 (ja) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
KR20140124398A (ko) 2012-02-07 2014-10-24 이올라스 테라퓨틱스, 인코포레이티드 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
TW201444821A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
AU2014358766B2 (en) * 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
NZ730334A (en) 2014-09-11 2023-01-27 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016095204A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor antagonists
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
RS63471B1 (sr) 2016-02-12 2022-08-31 Astrazeneca Ab Halo-supstituisani piperidini kao modulatori receptora oreksina
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
SE9803773D0 (sv) * 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
JP4794793B2 (ja) * 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
CA2408343A1 (en) * 2000-05-11 2002-11-07 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
EP1705179A1 (en) * 2001-06-28 2006-09-27 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0130341D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
ES2273083T3 (es) * 2002-09-18 2007-05-01 Glaxo Group Limited N-aroilaminas ciclicas como antagonistas de los receptores de orexina.
NZ541651A (en) * 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
JP2007523846A (ja) * 2003-04-28 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド キノキサリノン誘導体
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
ES2328400T3 (es) * 2005-04-21 2009-11-12 Boehringer Ingelheim International Gmbh Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias.
EP1950211A4 (en) 2005-11-18 2011-08-31 Eisai R&D Man Co Ltd PROCESS FOR PREPARING A CINEMA ACID AMID DERIVATIVE
JPWO2007058304A1 (ja) 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
BRPI0618814A2 (pt) 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
MX2008011221A (es) 2006-03-09 2008-09-11 Eisai R&D Man Co Ltd Compuestos de cinamida policiclicos.
AU2007252643A1 (en) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Urea type cinnamide derivative
CN101448797A (zh) 2006-05-19 2009-06-03 卫材R&D管理有限公司 杂环类型肉桂酰胺衍生物
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
EP2094685B1 (en) * 2006-12-01 2011-01-19 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
ATE525375T1 (de) * 2007-03-13 2011-10-15 Merck Sharp & Dohme Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
WO2008138753A1 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
CN101910142B (zh) 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂

Also Published As

Publication number Publication date
JP5395808B2 (ja) 2014-01-22
KR20100082807A (ko) 2010-07-19
US7897627B2 (en) 2011-03-01
IL205665A (en) 2014-01-30
IL205665A0 (en) 2010-11-30
WO2009080533A1 (en) 2009-07-02
PE20091173A1 (es) 2009-08-03
EP2234999A1 (en) 2010-10-06
AR069849A1 (es) 2010-02-24
CN101903372B (zh) 2014-06-18
JP2011506534A (ja) 2011-03-03
AU2008340421B2 (en) 2013-12-19
US20090163485A1 (en) 2009-06-25
AU2008340421A1 (en) 2009-07-02
KR101204213B1 (ko) 2012-11-26
TW200930362A (en) 2009-07-16
CA2705411A1 (en) 2009-07-02
BRPI0821141A2 (pt) 2015-06-16
CN101903372A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ME01532B (me) Jedinjenja
DOP2009000126A (es) Antagonistas de receptor de orexina de diazepan sustituído
CL2007001555A1 (es) Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos.
CR10020A (es) Antagonistas de los receptores 2 de dopamina de rapida disociación
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CL2008002808A1 (es) Compuestos derivados de benzoxazol, agonistas del receptor muscarinico m1; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamiento de esquizofrenia, alteraciones cognitivas o enfermedad de alzheimer.
CL2011002382A1 (es) Uso de un compuesto derivado de quinazolina-2,4-diona para el tratamiento y/o la prevencion de trastornos asociados al sistema nervioso central y/o al sistema nervioso periferico, preferentemente trastornos asociados a esquizofrenia, enfermedad de parkinson y enfermedad de alzheimer.
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
MD20160112A2 (ro) Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
CL2008003362A1 (es) Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands